ESR1 and ovarian cancer: A study by Smyth et al. reported an almost doubling of CA125 response rate for letrozole when patients with recurrent ovarian cancer were pre-selected for expression of the ER (9% in unselected vs 17% in ER+ patients) [15, 17].